Lifeward Ltd. 8-K

What Happened

• Lifeward Ltd. (LFWD) filed an 8-K on Feb 9, 2026 reporting that Nasdaq notified the company it did not meet the $1.00 minimum bid price rule and has granted an additional 180 days, extending the compliance deadline to August 3, 2026. The company had previously received a deficiency notice on August 5, 2025 and failed to regain compliance by the initial Feb 2, 2026 deadline.
• At an Extraordinary General Meeting on January 6, 2026 shareholders approved a reverse share split in a range of 1-for-2 to 1-for-12; the Board later approved a 1-for-12 reverse split, with timing to be determined, as one possible step to regain compliance.

Key Details

• Nasdaq deficiency notice dated August 5, 2025; initial 180-day cure period ended Feb 2, 2026.
• Nasdaq extended the cure period by 180 days to August 3, 2026.
• To cure, the closing bid must be at least $1.00 for a minimum of 10 consecutive business days.
• Shareholders approved a reverse split range Jan 6, 2026; Board selected a 1-for-12 split (implementation timing TBD).

Why It Matters

• If Lifeward does not meet the $1.00 bid requirement by Aug 3, 2026, Nasdaq may begin delisting procedures; the company can appeal to a Nasdaq Hearings Panel and shares would remain listed pending the hearing decision.
• A reverse split (1-for-12) could raise the per-share price and help meet Nasdaq’s rule, but the company has not set an implementation date and there is no guarantee compliance will be achieved.
• For investors, failure to regain compliance could reduce liquidity and limit trading options; conversely, a successful cure or appeal would preserve Nasdaq listing.